Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Childhood Sjögren syndrome: features of an international cohort and application of the 2016 ACR/EULAR classification criteria
Basiaga, Matthew L. , Stern, Sara , Edens, Cuoghi , Randell, Rachel L. , Pomorska, Anna , Ibarra, Maria, Nicolai, Rebecca , Sušić, Gordana , Boneparth, Alexis , Dizon, Brian , Kamdar, Ankur, Goldberg, Baruch R., Knupp-Oliveira, Sheila, Mosquera, Juan Manuel , Appenzeller, Simone , O’Neil, Kathleen M., Protopapas, Stella , Saad‐Magalhães, Claudia , Akikusa, Jonathan , Thatayatikom, Akaluck , Cha, Seunghee , Nieto‐González, Juan Carlos , Lo, Mindy S. , Lieberman, Scott M. , Randell, Rachel L , Mehta, Jay , Irga‐Jaworska, Ninela , Bracaglia, Claudia , Srinivasalu, Hemalatha , Antón, Jordi , Treemarcki, Erin , Yokogawa, Naoto

Mayo Clinic

Rheumatology | October 28, 2020 | Volume: 60 | Issue: 7 | Pages: 3144-3155

10.1093/rheumatology/keaa757 | PMID 33280020 Get It

Abstract Objective Sjögren syndrome in children is a poorly understood autoimmune disease. We aimed to describe the clinical and diagnostic features of children diagnosed with Sjögren syndrome and explore how the 2016 ACR/EULAR classification criteria apply to this population. Methods An international workgroup retrospectively collected cases of Sjögren syndrome diagnosed under 18 years of age from 23 centres across eight nations. We analysed patterns of symptoms, diagnostic workup, and applied the 2016 ACR/EULAR classification criteria. Results We identified 300 children with Sjögren syndrome. The majority of patients n = 232 (77%) did not meet 2016 ACR/EULAR classification criteria, but n = 110 (37%) did not have sufficient testing done to even possibly achieve the score necessary to meet criteria. Even among those children with all criteria items tested, only 36% met criteria. The most common non-sicca symptoms were arthralgia [n = 161 (54%)] and parotitis [n = 140 (47%)] with parotitis inversely correlating with age. Conclusion Sjögren syndrome in children can present at any age. Recurrent or persistent parotitis and arthralgias are common symptoms that should prompt clinicians to consider the possibility of Sjögren syndrome. The majority of children diagnosed with Sjögren syndromes did not meet 2016 ACR/EULAR classification criteria. Comprehensive diagnostic testing from the 2016 ACR/EULAR criteria are not universally performed. This may lead to under-recognition and emphasizes a need for further research including creation of paediatric-specific classification criteria.
Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials
Ellingson, Benjamin M. , Boxerman, Jerrold L. , Gerstner, Elizabeth R. , Cole, Patricia E., Bacha, Jeffrey , Leung, David , Barone, Amy , Colman, Howard , Bent, Martin J. van den , Wen, Patrick Y. , Yung, W.K. Alfred, van den Bent, Martin J , Ellingson, Benjamin M , Brown, Matthew S. , Kaufmann, Timothy J. , Colman, Howard , Wen, Patrick Yung , Cloughesy, Timothy F. , Goldin, Jonathan

Mayo Clinic

Neuro-Oncology | October 26, 2020 | Volume: 23 | Issue: 2 | Pages: 189-198

10.1093/neuonc/noaa253 | PMID 33130879 Get It

Abstract Determination of therapeutic benefit in intracranial tumors is intimately dependent on serial assessment of radiographic images. The Response Assessment in Neuro-Oncology (RANO) criteria were established in 2010 to provide an updated framework to better characterize tumor response to contemporary treatments. Since this initial update a number of RANO criteria have provided some basic principles for the interpretation of changes on MR images; however, the details of how to operationalize RANO and other criteria for use in clinical trials are ambiguous and not standardized. In this review article designed for the neuro-oncologist or treating clinician, we outline essential steps for performing radiographic assessments by highlighting primary features of the Imaging Charter (referred to as the Charter for the remainder of this article), a document that describes the clinical trial imaging methodology and methods to ensure operationalization of the Charter into the workings of a clinical trial. Lastly, we provide recommendations for specific changes to optimize this methodology for neuro-oncology, including image registration, requirement of growing tumor for eligibility in trials of recurrent tumor, standardized image acquisition guidelines, and hybrid reader paradigms that allow for both unbiased measurements and more comprehensive interpretation.
S0470 The Impact of Plecanatide on Abdominal Pain in Patients With Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation: Analysis From Four Phase 3 Studies
Bharucha, Adil E. , Rosenberg, Jonathan , Patel, Reema, Lorenzen, Sarah, Sayuk, Gregory S.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S236-S236

10.14309/01.ajg.0000703928.35944.4e Get It

Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer
Fernández-Martínez, Aranzazu , Krop, Ian E. , Hillman, David W. , Polley, Mei‐Yin C. , Huebner, Lucas J. , Hoadley, Katherine A. , Shepherd, Jonathan H. , Tolaney, Sara M. , Henry, N. Lynn , Dang, Chau T. , Harris, Lyndsay N. , Berry, Donald A. , Hahn, Olwen, Hudis, Clifford A. , Perou, Charles M. , Polley, Mei-Yin , Huebner, Lucas , Hoadley, Katherine A , Tolaney, Sara , Henry, N Lynn , Berry, Donald , Hudis, Clifford , Winer, Eric , Partridge, Ann H , Perou, Charles M , Hillman, David W , Parker, Joel S. , Winer, Eric P. , Partridge, Ann H. , Carey, Lisa A. , Shepherd, Jonathan H. , Fernandez-Martinez, Aranzazu

Mayo Clinic

Journal of Clinical Oncology | October 23, 2020 | Volume: 38 | Issue: 35 | Pages: 4184-4193

10.1200/jco.20.01276 | PMID 33095682 Get It

PURPOSE CALGB 40601 assessed whether dual versus single human epidermal growth factor receptor 2 (HER2) –targeting drugs added to neoadjuvant chemotherapy increased pathologic complete response (pCR). Here, we report relapse-free survival (RFS), overall survival (OS), and gene expression signatures that predict pCR and survival. PATIENTS AND METHODS Three hundred five women with untreated stage II and III HER2-positive breast cancer were randomly assigned to receive weekly paclitaxel combined with trastuzumab plus lapatinib (THL), trastuzumab (TH), or lapatinib (TL). The primary end point was pCR, and secondary end points included RFS, OS, and gene expression analyses. mRNA sequencing was performed on 264 pretreatment samples. RESULTS One hundred eighteen patients were randomly allocated to THL, 120 to TH, and 67 to TL. At more than 7 years of follow-up, THL had significantly better RFS and OS than did TH (RFS hazard ratio, 0.32; 95% CI, 0.14 to 0.71; P = .005; OS hazard ratio, 0.34; 95% CI, 0.12 to 0.94; P = .037), with no difference between TH and TL. Of 688 previously described gene expression signatures, significant associations were found in 215 with pCR, 45 with RFS, and only 22 with both pCR and RFS (3.2%). Specifically, eight immune signatures were significantly correlated with a higher pCR rate and better RFS. Among patients with residual disease, the immunoglobulin G signature was an independent, good prognostic factor, whereas the HER2-enriched signature, which was associated with a higher pCR rate, showed a significantly shorter RFS. CONCLUSION In CALGB 40601, dual HER2-targeting resulted in significant RFS and OS benefits. Integration of intrinsic subtype and immune signatures allowed for the prediction of pCR and RFS, both overall and within the residual disease group. These approaches may provide means for rational escalation and de-escalation treatment strategies in HER2-positive breast cancer.
Comparison of reconstructive techniques following oncologic intraarticular resection of proximal humerus
Houdek, Matthew T. , Bukowski, Brandon R., Athey, Alexander G., Elhassan, Bassem T. , Rose, Peter S. , Barlow, Jonathan D. , Sanchez-Sotelo, Joaquin, Houdek, Matthew T , Morrey, Mark E. , Wagner, Eric R. , Sánchez‐Sotelo, Joaquín

Mayo Clinic

Journal of Surgical Oncology | October 23, 2020 | Volume: 123 | Issue: 1 | Pages: 133-140

10.1002/jso.26271 | PMID 33095924 Get It

AbstractIntroductionThe proximal humerus is a common site of primary and metastatic disease in the upper extremity. Historically, the goal of a hemiarthroplasty reconstruction was to provide a stable platform for hand and elbow function, with limited shoulder function. Techniques utilizing a reverse endoprosthesis (endoprosthetic replacement [EPR]) and allograft‐prosthetic composite (APC) have been developed; however, there is a paucity of comparative studies.MethodsA total of 83 (42 females, 41 males) patients undergoing an intraarticular resection of the humerus were reviewed. Reconstructions included 30 reverse and 53 hemiarthroplasty; including hemiarthroplasty EPR (n = 36) and APC (n = 17), and reverse EPR (n = 20) and APC (n = 10).ResultsReverse reconstructions had improved forward elevation (85° vs. 44°, p < .001) and external rotation (30° vs. 21°; p < .001) versus a hemiarthroplasty. Reverse reconstructions had improved American Shoulder and Elbow Surgeons scores (65 vs. 57; p = .01) and Musculoskeletal Tumor Society 93 scores (72 vs. 63; p < .001) versus hemiarthroplasty. Subluxation of the reconstruction was a common (n = 23, 27%), only occurring in hemiarthroplasty patients (EPR [n = 13, 36%] and APC [n = 10, 59%]).ConclusionThe current series highlights the improved functional outcome in patients undergoing reconstruction with a reverse arthroplasty compared to the traditional hemiarthroplasty. Currently reverse shoulder arthroplasty (APC or EPR) is our preferred methods of reconstruction in this patient population.
Does Portrayal of Skin Tone in Gender-Affirming Literature Represent Diversity?
Davis, Matthew , Shen, Jacson K., Cen, Nicholas, Kneib, Cameron J. , Cho, Daniel , Massie, Jonathan P. , Vyas, Krishna S. , Streed, Carl G. , Satterwhite, Thomas, Abu‐Ghname, Amjed , Patel, Viren , Seebacher, Nicole A. , Morrison, Shane D.

Mayo Clinic

LGBT Health | October 21, 2020 | Volume: 7 | Issue: 8 | Pages: 461-463

10.1089/lgbt.2020.0207 | PMID 33085918 Get It

Electronic DNA Analysis of CSF Cell-free Tumor DNA to Quantify Multi-gene Molecular Response in Pediatric High-grade Glioma
Bruzek, Amy K., Ravi, Karthik , Muruganand, Ashwath, Wadden, Jack , Babila, Clarissa May, Cantor, Evan , Tunkle, Leo, Wierzbicki, Kyle , Stallard, Stefanie, Dickson, Robert P. , Wolfe, Ian, Mody, Rajen , Schwartz, Jonathan , Franson, Andrea , Robertson, Patricia L. , Muraszko, Karin M. , Maher, Cormac O. , Garton, Hugh , Qin, Tingtin, Franson, Andrea , Ravi, Karthik , Koschmann, Carl

Mayo Clinic

Clinical Cancer Research | October 21, 2020 | Volume: 26 | Issue: 23 | Pages: 6266-6276

10.1158/1078-0432.ccr-20-2066 | PMID 33087334 Get It

Abstract Purpose: Pediatric high-grade glioma (pHGG) diagnosis portends poor prognosis and therapeutic monitoring remains difficult. Tumors release cell-free tumor DNA (cf-tDNA) into cerebrospinal fluid (CSF), allowing for potential detection of tumor-associated mutations by CSF sampling. We hypothesized that direct, electronic analysis of cf-tDNA with a handheld platform (Oxford Nanopore MinION) could quantify patient-specific CSF cf-tDNA variant allele fraction (VAF) with improved speed and limit of detection compared with established methods. Experimental Design: We performed ultra-short fragment (100–200 bp) PCR amplification of cf-tDNA for clinically actionable alterations in CSF and tumor samples from patients with pHGG (n = 12) alongside nontumor CSF (n = 6). PCR products underwent rapid amplicon-based sequencing by Oxford Nanopore Technology (Nanopore) with quantification of VAF. Additional comparison to next-generation sequencing (NGS) and droplet digital PCR (ddPCR) was performed. Results: Nanopore demonstrated 85% sensitivity and 100% specificity in CSF samples (n = 127 replicates) with 0.1 femtomole DNA limit of detection and 12-hour results, all of which compared favorably with NGS. Multiplexed analysis provided concurrent analysis of H3.3A (H3F3A) and H3C2 (HIST1H3B) mutations in a nonbiopsied patient and results were confirmed by ddPCR. Serial CSF cf-tDNA sequencing by Nanopore demonstrated correlation of radiological response on a clinical trial, with one patient showing dramatic multi-gene molecular response that predicted long-term clinical response. Conclusions: Nanopore sequencing of ultra-short pHGG CSF cf-tDNA fragments is feasible, efficient, and sensitive with low-input samples thus overcoming many of the barriers restricting wider use of CSF cf-tDNA diagnosis and monitoring in this patient population.
Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group
Lautz, Timothy B. , Li, Minjie , Casey, Dana L. , Routh, Jonathan C. , Granberg, Candace F. , Binite, Odion, Rudzinski, Erin R. , Hawkins, Douglas S. , Venkatramani, Rajkumar , Rodeberg, David A. , Casey, Dana L , Routh, Jonathan C , Hawkins, Douglas S , Lautz, Timothy , Chi, Yueh‐Yun , Wolden, Suzanne L.

Mayo Clinic

Cancer | October 20, 2020 | Volume: 127 | Issue: 2 | Pages: 275-283

10.1002/cncr.33275 | PMID 33079399 Get It

Background Most children with intermediate‐risk rhabdomyosarcoma (RMS) have gross disease (group III) at the initiation of chemotherapy. Delayed primary excision (DPE) after induction chemotherapy allows for a reduction in adjuvant radiation dose, but with the risk of potential surgical morbidity. The objectives of this study were to compare outcomes in children with group III RMS who did and did not undergo DPE and to assess surgical morbidity. Methods The study included 369 patients who had clinical group III RMS at sites amenable to DPE from intermediate‐risk Children's Oncology Group studies D9803 (encouraged DPE) and ARST0531 (discouraged DPE). Results The primary tumor site was bladder/prostate (136 patients; 37%), extremity (97 patients; 26%), trunk (24 patients; 7%), retroperitoneum (91 patients; 25%), or intrathoracic/perineum/perianal (21 patients; 6%). In total, 112 patients (53.9%) underwent DPE in D9803, and 26 patients (16.2%) underwent DPE in ARST0531 ( P < .001), with loss of vital organ or function in 30 of 138 patients (22%). DPE allowed for a reduced radiation dose in 110 of 135 patients (81%; 51% were reduced to 36 Gy, and 30% were reduced to 42 Gy). Patients who underwent DPE had improved unadjusted overall survival ( P = .013). In adjusted regression analysis, the risk of death (hazard ratio, 0.71; 95% CI 0.43‐1.16) was similar for patients who did and did not undergo DPE and was improved for the subset of patients who had tumors of the trunk and retroperitoneum (hazard ratio, 0.44; 95% CI, 0.20‐0.97). Conclusions Children with group III RMS have equivalent or improved outcomes with DPE and can receive a decreased radiation dose for definitive local control. The choice of local control modality should weigh the potential morbidity of surgery versus that of higher dose irradiation.
Clinical commissioning of intensity‐modulated proton therapy systems: Report of AAPM Task Group 185
Farr, Jonathan B., Moyers, Michael F. , Allgower, C., Hsi, W, Jin, Hosang , Mihailidis, D, Lu, Hsiao‐Ming , Newhauser, Wayne , Sahoo, Narayan , Slopsema, R , Yeung, Daniel , Zhu, X , Bues, Martin

Mayo Clinic

Medical Physics | October 20, 2020 | Volume: 48 | Issue: 1 | Pages: No page available

10.1002/mp.14546 | PMID 33078858 Get It

Proton therapy is an expanding radiotherapy modality in the United States and worldwide. With the number of proton therapy centers treating patients increasing, so does the need for consistent, high‐quality clinical commissioning practices. Clinical commissioning encompasses the entire proton therapy system's multiple components, including the treatment delivery system, the patient positioning system, and the image‐guided radiotherapy components. Also included in the commissioning process are the x‐ray computed tomography scanner calibration for proton stopping power, the radiotherapy treatment planning system, and corresponding portions of the treatment management system. This commissioning report focuses exclusively on intensity‐modulated scanning systems, presenting details of how to perform the commissioning of the proton therapy and ancillary systems, including the required proton beam measurements, treatment planning system dose modeling, and the equipment needed.
A Case Series of Long-Term Surgical Outcomes of Primary Pulmonary Artery Sarcomas With Opportunities for 3D-Printed Models in Surgical Planning
Mahajan, Nandita , Çïçek, Sertaç , McGregor, Christopher G.A. , Okuno, Scott H. , White, Darin , Yi, Eunhee S. , Mahajan, Nandita N , Çiçek, Sertaç M, Boland, Jennifer M. , Blackmon, Shanda H, Morris, Jonathan M. , Robinson, Steven I. , Blackmon, Shanda

Mayo Clinic

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery | October 20, 2020 | Volume: 16 | Issue: 1 | Pages: 94-100

10.1177/1556984520960716 | PMID 33076737 Get It

There are limited data regarding the surgical management of primary pulmonary artery sarcomas (PPAS) because of their rarity and complicated diagnostic history. The objective of this study was to analyze our institution’s long-term surgical management outcomes for PPAS in the absence of a care pathway. From May 1997 to June 2013, 8 patients (mean age 60.6 ± 11.8 years; range, 40-73 years; 5 women and 3 men) underwent surgical intervention for PPAS at our institution. The most common computed tomography finding was a luminal filling defect obstructing the pulmonary artery (PA), without evidence of extraluminal extension. Three patients underwent debulking/pulmonary endarterectomy alone and 5 patients underwent a more radical resection with PA patch angioplasty, PA resection and reconstruction, pulmonary valve replacement, and unilateral pneumonectomy. The mean postoperative survival in this series was 3.8 ± 3.6 years (range, 1-11.9 years), with 2 radical surgical resection patients alive at 4.9 and 11.9 years, respectively. For those patients with incomplete resection, 3-dimensional (3D) models were created to demonstrate the advantage of a preoperative guide for a more complete resection and what it would entail. Six patients had local recurrences with mean disease-free interval of 14 ± 10.9 months (range, 2 months-2.5 years), and 2 patients with re-resections had an overall postoperative survival of 2.8 and 11.9 years, respectively. In our small cohort of PPAS, patients treated with radical surgical resection had better survival. The small number of PPAS cases in this series makes proving this association unlikely but warrants consideration.